Certara, Inc.

Listed Company

CERTCIK 0001827090NasdaqLarge AcceleratedServices-Prepackaged SoftwareDelawareFY ends Dec 31

Period

FY 2025

Revenue

$418.84M

Net Income

$-1.59M

Total Assets

$1.56B

Equity

$1.06B

Shares Out

155.56M

Op. Cash Flow

$96.33M

CERT$6.91−34.44% · past yearDBEQ Basic

Daily closing prices

Business

Certara, Inc. is a global provider of biosimulation science, technology, and consulting services for Model-Informed Drug Development in the biopharmaceutical and biotech industry. The company offers mechanistic and empirical biosimulation software platforms (Simcyp Simulator, Phoenix suite), clinical data management and regulatory science solutions (Pinnacle 21, CoAuthor, GlobalSubmit), and technology-enabled consulting services delivered by experienced scientists. Certara serves life sciences companies, contract research organizations, and regulatory agencies across drug discovery, development, and commercialization, with customers driving a substantial majority of novel FDA drug approvals.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	419	385	354	336	286
Cost of revenues	161	155	141	133	—
Sales and marketing	54	47	32	27	20
Research and development	41	37	34	28	20
General and administrative	85	94	95	72	80
Depreciation and amortization	57	54	46	2	2
Goodwill impairment expense	0	0	47	0	0
Total operating expenses	237	232	254	171	161
Income (loss) from operations	21	−2	−41	33	14
Interest expense	−20	−22	−23	−18	—
Net other income	6	6	9	−14	−17
Total other expenses	−13	−15	−14	—	—
Income (loss) before income taxes	8	−17	−55	19	−3
Provision (benefit) for income taxes	9	−5	214,000	4	10
Net loss	−2	−12	−55	15	−13
Foreign currency translation adjustment, net of tax of $6, $(956), $(717)	19	−3	3	−10	−5
Change in fair value of interest rate swap, net of tax of $253, $$(827), $1,393	−3	−3	−2	6	—
Total other comprehensive income (loss)	15	−6	637,000	−4	−2
Comprehensive income (loss)	14	−18	−55	10	−16
Basic (in dollars per share)	−0.01	−0.08	−0.35	0.09	−0.09
Diluted (in dollars per share)	−0.01	−0.08	−0.35	0.09	−0.09
Basic (in shares)	160	160	159	157	150
Diluted (in shares)	160	160	159	159	150

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	189	179	235	237	186
Accounts receivable, net of allowances for credit losses of $2,235 and $2,164, respectively	104	102	85	83	70
Prepaid expenses and other current assets	22	29	20	20	19
Total current assets	315	311	340	342	275
Property and equipment, net	2	2	3	2	3
Operating lease right-of-use assets	12	14	10	14	13
Goodwill	773	757	716	718	703
Intangible assets, net of accumulated amortization of $415,804 and $338,809, respectively	447	485	487	487	512
Deferred income taxes	5	4	4	4	4
Other long-term assets	2	2	3	6	2
Total assets	1,557	1,575	1,563	1,573	1,512
Accounts payable	3	4	5	8	7
Accrued expenses	67	56	57	35	30
Current portion of deferred revenue	75	78	61	52	45
Current portion of long-term debt	3	3	3	3	3
Other current liabilities	4	5	4	5	1
Total current liabilities	153	146	130	103	92
Deferred revenue, net of current portion	2	1	1	3	2
Deferred income taxes	34	40	51	65	76
Operating lease liabilities, net of current portion	8	11	7	10	8
Long-term debt, net of current portion and debt discount	290	292	288	290	292
Other long-term liabilities	5	25	39	22	25,000
Total liabilities	494	516	516	493	470
Commitments and contingencies	—	—	—	—	—
Preferred shares, $0.01 par value, 50,000,000 and no shares authorized, issued, and outstanding as of December 31, 2025 and 2024, respectively	0	0	0	—	—
Common shares, $0.01 par value, 600,000,000 shares authorized, 164,005,450 and 161,958,810 shares issued as of December 31, 2025 and 2024, respectively; 159,139,562 and 161,009,112 shares outstanding as of December 31, 2025 and 2024, respectively	2	2	2	2	—
Additional paid-in capital	1,256	1,217	1,178	1,150	1,120
Accumulated deficit	−130	−128	−116	−61	−76
Accumulated other comprehensive income(loss)	2	−13	−8	−8	−4
Treasury stock at cost, 4,865,888 and 949,698 shares at December 31, 2025 and 2024, respectively	−67	−18	−9	−3	−38,000
Total stockholders' equity	1,063	1,059	1,047	1,080	1,042
Total liabilities and stockholders' equity	1,557	1,575	1,563	1,573	1,512

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	75	68	56	2	2
Amortization of debt issuance costs	568,000	1	2	2	2
Provision for credit losses	1	1	684,000	1	130,000
Equity-based compensation expense	33	35	28	30	29
Change in fair value of contingent considerations	−4	8	24	0	0
Total deferred	−8	−13	−17	−12	−1
Accounts receivable	428,000	−16	152,000	−15	−10
Prepaid and other assets	−902,000	−3	711,000	126,000	585,000
Accounts payable and accrued expenses, and other liabilities	4	−5	−6	9	1
Deferred revenue	−3	14	28,000	10	5
Other operating activities, net	−1	—	—	—	—
Other operating activities, net	—	2	2	169,000	—
Net cash provided by operating activities	96	80	83	93	60
Capital expenditures	−2	−2	−2	−1	−1
Capitalized software development costs	−25	−19	−13	−11	−8
Investment in intangible assets	0	0	−54,000	0	0
Business acquisitions, net of cash acquired	0	−91	−64	−15	−261
Net cash used in investing activities	−27	−112	−80	−28	−270
Common stock repurchase program	−43	0	0	—	—
Proceeds from borrowings on term loan debt	0	6	0	0	—
Payment of debt issuance costs	0	−1	0	0	−3
Payments on long-term debt obligations	−3	−2	−3	−3	—
Payments for business acquisition related contingent consideration	−13	−15	0	0	—
Payment of taxes on shares and units withheld for employee taxes	−5	−9	−6	−3	−272,000
Net cash used in financing activities	−64	−21	−9	−7	123
Effect of foreign exchange rate changes on cash and cash equivalents	4	−3	2	−4	−524,000
Net increase (decrease) in cash, cash equivalents	10	−56	−5	53	−87
Cash paid for interest	19	23	19	17	14
Cash paid for taxes	12	15	19	10	9
Contingent liabilities established in connection with business acquisition	0	0	11	20	0
Stock issuance or establish liabilities related to business acquisition contingent consideration	6	4	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Certara, Inc.'s CIK number?

Certara, Inc.'s SEC CIK number is 0001827090 (1827090). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Certara, Inc.'s SEC filings?

All of Certara, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Certara, Inc. last report earnings?

Certara, Inc. (CERT) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001827090-26-000017). This is Certara, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Certara, Inc.'s most recent earnings 8-K?

Certara, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001827090-26-000017. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Certara, Inc.'s latest earnings 8-K →
Look up any company's CIK number →